User profiles for "author:John Frew"

John W Frew

University of New South Wales
Verified email at unsw.edu.au
Cited by 3016

What causes hidradenitis suppurativa?—15 years after

CC Zouboulis, F Benhadou, AS Byrd… - Experimental …, 2020 - Wiley Online Library
The 14 authors of the first review article on hidradenitis suppurativa (HS) pathogenesis
published 2008 in EXPERIMENTAL DERMATOLOGY cumulating from the 1st International …

Psoriasis in those planning a family, pregnant or breast‐feeding. The Australasian Psoriasis Collaboration

M Rademaker, K Agnew, M Andrews… - Australasian Journal …, 2018 - Wiley Online Library
Abstract The Australasian Psoriasis Collaboration has reviewed the evidence for managing
moderate to severe psoriasis in those who are pregnant or are breast‐feeding, or planning a …

Identification of biomarkers and critical evaluation of biomarker validation in hidradenitis suppurativa: a systematic review

S Der Sarkissian, S Hessam, JS Kirby… - JAMA …, 2022 - jamanetwork.com
Importance The identification and validation of biomarkers in hidradenitis suppurativa (HS)
has potential to improve the understanding and management of this chronic, burdensome …

[HTML][HTML] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international …

DH Brand, AC Tree, P Ostler, H van der Voet… - The Lancet …, 2019 - thelancet.com
Background Localised prostate cancer is commonly treated with external-beam
radiotherapy. Moderate hypofractionation has been shown to be non-inferior to conventional …

[HTML][HTML] Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised …

AC Tree, P Ostler, H van der Voet, W Chu… - The Lancet …, 2022 - thelancet.com
Background Localised prostate cancer is commonly treated with external beam radiotherapy
and moderate hypofractionation is non-inferior to longer schedules. Stereotactic body …

Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth …

T Powles, RA Huddart, T Elliott… - Journal of Clinical …, 2017 - eprints.soton.ac.uk
Purpose: To establish whether maintenance lapatinib after first-line chemotherapy is
beneficial in human epidermal growth factor receptor (HER) 1/HER2-positive metastatic …

Critical role of c-jun (NH2) terminal kinase in paracetamol-induced acute liver failure

NC Henderson, KJ Pollock, J Frew, AC Mackinnon… - Gut, 2007 - gut.bmj.com
Background: Acute hepatic failure secondary to paracetamol poisoning is associated with
high mortality. C-jun (NH2) terminal kinase (JNK) is a member of the mitogen-activated …

COVID-19 and immunomodulator/immunosuppressant use in dermatology

KN Price, JW Frew, JL Hsiao, VY Shi - Journal of the American academy of …, 2020 - jaad.org
To the Editor: We read with great interest the Commentary by Lebwohl et al 1 recently
published in the Journal of the American Academy of Dermatology. The authors provided a …

The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study

JW Frew, K Navrazhina, D Grand… - Journal of the American …, 2020 - Elsevier
Background Hidradenitis suppurativa is an autoinflammatory disorder of keratinization, with
dysregulation of T helper type 17 cytokines. Brodalumab is a monoclonal antibody that …

A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa

SS Venugopal, W Yan, JW Frew, HI Cohn… - Journal of the American …, 2013 - Elsevier
Background Chronic wounds are a major source of morbidity and mortality in generalized
severe recessive dystrophic epidermolysis bullosa (RDEB-GS). Objective This was a phase …